title: A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.
abstract: OBJECTIVE
  To estimate the budget impact of the introduction of biosimilar infliximab for the treatment of Crohn's disease (CD) in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia.
  
  
  METHODS
  A 3-year, prevalence-based budget impact analysis for biosimilar infliximab to treat CD was developed from third-party payers' perspective. The model included various scenarios depending on whether interchanging originator infliximab with biosimilar infliximab was allowed or not.
  
  
  RESULTS
  Total cost savings achieved in biosimilar scenario 1 (interchanging not allowed) and BSc2 (interchanging allowed in 80% of the patients) were estimated to €8.0 million and €16.9 million in the six countries. Budget savings may cover the biosimilar infliximab therapy for 722-1530 additional CD patients.
  
  
  CONCLUSIONS
  Introduction of biosimilar infliximab to treat CD may offset the inequity in access to biological therapy for CD between Central and Eastern European countries.
authors.affiliation: a 1 Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary.
authors.forename: Valentin
authors.initials: V
authors.lastname: Brodszky
authors.affiliation: a 1 Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary.|b 2 Semmelweis University Doctoral School of Clinical Medicine, Üllői út 26, H-1085 Budapest, Hungary.
authors.forename: Fanni
authors.initials: F
authors.lastname: Rencz
authors.affiliation: a 1 Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary.
authors.forename: Márta
authors.initials: M
authors.lastname: Péntek
authors.affiliation: a 1 Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary.
authors.forename: Petra
authors.initials: P
authors.lastname: Baji
authors.affiliation: c 3 First Department of Medicine, Semmelweis University, Koranyi S. 2/A, H-1083 Budapest, Hungary.
authors.forename: Péter L
authors.initials: PL
authors.lastname: Lakatos
authors.affiliation: a 1 Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093 Budapest, Hungary.
authors.forename: László
authors.initials: L
authors.lastname: Gulácsi
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000008:administration & dosage* / Q000191:economics; D002017:Budgets; D017046:Cost Savings; D003424:Crohn Disease / Q000188:drug therapy* / Q000191:economics; D005061:Europe, Eastern; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D000069285:Infliximab / Q000008:administration & dosage* / Q000191:economics; D007349:Insurance, Health, Reimbursement / Q000191:economics; D018803:Models, Economic
chemical_list: D059451:Biosimilar Pharmaceuticals; D005765:Gastrointestinal Agents; D000069285:Infliximab
keywords: Central and Eastern Europe; Crohn’s disease; biosimilar drugs; budget impact analysis; inflammatory bowel diseases; infliximab